|
Liver carcinoma
|
0.360 |
Biomarker
|
disease |
BEFREE |
Targeting DTL induces cell cycle arrest and senescence and suppresses cell growth and colony formation through TPX2 inhibition in human hepatocellular carcinoma cells.
|
29606879 |
2018 |
|
Liver carcinoma
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
Subgroup analysis revealed that increased TPX2 expression was related to worse prognosis of gastric cancer and hepatocellular cancer, while irrelevant to esophageal squamous cell cancer at 5-year survival rate.
|
30412141 |
2018 |
|
Liver carcinoma
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
Two other Ags (HCA519 and HCA90) were highly overexpressed in HCC and also expressed in cancer cell lines of lung, prostate, and pancreas, but not in the respective normal tissues.
|
12097419 |
2002 |
|
Liver carcinoma
|
0.360 |
Biomarker
|
disease |
BEFREE |
Totally, 427 upregulated (e.g., cell division cycle associated 5 [<i>CDCA5</i>], kinesin family member 4A [<i>KIF4A</i>], TPX2 microtubule nucleation factor [<i>TPX2</i>]) and 313 downregulated (e.g., metallothionein 1E [<i>MT1E</i>]) DEGs were identified in HCC.
|
31593490 |
2019 |
|
Liver carcinoma
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
In this study, increased TPX2 protein expression was present in 16 (42%) of 38 primary HCCs and was associated with advanced stage, distant metastatic HCCs and poor prognosis.
|
28638452 |
2017 |
|
Liver carcinoma
|
0.360 |
Biomarker
|
disease |
BEFREE |
We finally extracted four genes, AKR1B10, HCAP-G, RRM2, and TPX2, as candidate therapeutic targets for HCC. siRNA-mediated knockdown of these candidate genes inhibited the proliferation of HCC cells and the growth of HCC xenografts transplanted into immunodeficient mice.
|
20388846 |
2010 |
|
Liver carcinoma
|
0.360 |
Biomarker
|
disease |
CTD_human |
Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
|
28284560 |
2017 |
|
Colorectal Carcinoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
After the generation of a profile of genes overexpressed in primary colorectal cancer (CRC) we selected 5 genes, Ese-3b, Fls353, PBEF, SPARC and Smad5 for a more detailed analysis using phage display-derived antibodies.
|
12209988 |
2002 |
|
Colorectal Carcinoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
Additionally, combined high expression of MYC, AURKA and TPX2 proved to be a poor prognostic indicator of colorectal cancer patient survival.
|
25632068 |
2015 |
|
Colorectal Carcinoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Twelve genes, including Smad5 and Fls353, have previously been shown to be overexpressed in CRC.
|
10601642 |
1999 |
|
Colorectal Carcinoma
|
0.330 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Malignant neoplasm of breast
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
Following on these observations, we further assessed the link between the AURKA-HMMR-TPX2-TUBG1 functional module and risk of breast cancer in BRCA1 or BRCA2 mutation carriers.
|
25830658 |
2015 |
|
Malignant neoplasm of breast
|
0.050 |
Biomarker
|
disease |
BEFREE |
Opposing roles of Nfkb2 gene products p100 and p52 in the regulation of breast cancer stem cells.
|
28190248 |
2017 |
|
Malignant neoplasm of breast
|
0.050 |
Biomarker
|
disease |
BEFREE |
Tpx2, the most highly connected gene within a proliferation network specifically prognostic for estrogen receptor positive (ER+) breast cancers, enhances metastatic disease, but in a tumor autonomous, proliferation-independent manner.
|
25368990 |
2014 |
|
Malignant neoplasm of breast
|
0.050 |
Biomarker
|
disease |
BEFREE |
In short, all the results suggested that miR-491 functioned as a tumor suppressor by targeting TPX2 in BC and the miR-491 restoration may be an effective therapy for the BC treatment in the future.
|
31799669 |
2019 |
|
Malignant neoplasm of breast
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
However, although p100 is highly expressed in a number of breast cancer cell lines, MHC Class I antigen expression was observed on all the cell lines we analysed and could be further induced by stimulation with the cytokines IFN-gamma or TNF-alpha.
|
9681829 |
1998 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
In short, all the results suggested that miR-491 functioned as a tumor suppressor by targeting TPX2 in BC and the miR-491 restoration may be an effective therapy for the BC treatment in the future.
|
31799669 |
2019 |
|
Breast Carcinoma
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Following on these observations, we further assessed the link between the AURKA-HMMR-TPX2-TUBG1 functional module and risk of breast cancer in BRCA1 or BRCA2 mutation carriers.
|
25830658 |
2015 |
|
Breast Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
However, although p100 is highly expressed in a number of breast cancer cell lines, MHC Class I antigen expression was observed on all the cell lines we analysed and could be further induced by stimulation with the cytokines IFN-gamma or TNF-alpha.
|
9681829 |
1998 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Opposing roles of Nfkb2 gene products p100 and p52 in the regulation of breast cancer stem cells.
|
28190248 |
2017 |
|
Malignant tumor of cervix
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, we validated that upregulation of TPX2 by hsa_circRNA_101996-mediated inhibition of miR-8075 contributed to cervical cancer proliferation, migration, and invasion.
|
30633364 |
2019 |
|
Malignant tumor of cervix
|
0.030 |
Biomarker
|
disease |
BEFREE |
In conclusion, TPX2 shows potential to be used as a new marker for cervical cancer diagnosis and therapy.
|
22307108 |
2012 |
|
Malignant tumor of cervix
|
0.030 |
Biomarker
|
disease |
BEFREE |
The results demonstrated that TPX2 is important in the regulation of tumor growth in cervical cancer and therefore may be a potential therapeutic target as a novel treatment strategy.
|
24718984 |
2014 |
|
Multiple Myeloma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
C-terminal truncations of the NFKB2 p100 gene product have been observed in a number of cases of human cutaneous T cell lymphomas, as well as human B-cell lymphomas and myelomas.
|
10713675 |
2000 |
|
Multiple Myeloma
|
0.030 |
Biomarker
|
disease |
BEFREE |
The molecular mechanism of p100 degradation has implications in multiple myeloma, a disease with constitutive activation of the noncanonical NF-κB pathway.
|
23211527 |
2012 |